Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion
Purpose: After 48 months, unresolved macular edema secondary to central retinal vein occlusion (CRVO) is present in more than half of the patients treated with ranibizumab/bevacizumab. Switching therapy to aflibercept, a more recent vascular endothelial growth factor-A (VEGF-A) inhibitor, as well as...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 29, 2015
|
| In: |
Ophthalmic research
Year: 2015, Volume: 54, Issue: 3, Pages: 150-156 |
| ISSN: | 1423-0259 |
| DOI: | 10.1159/000439223 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000439223 Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/439223 
|
| Author Notes: | Maximilian Pfau, Heidi Fassnacht-Riederle, Matthias D. Becker, Nicole Graf, Stephan Michels |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1703416899 | ||
| 003 | DE-627 | ||
| 005 | 20220818141611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200703s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000439223 |2 doi | |
| 035 | |a (DE-627)1703416899 | ||
| 035 | |a (DE-599)KXP1703416899 | ||
| 035 | |a (OCoLC)1341344562 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pfau, Maximilian |d 1991- |e VerfasserIn |0 (DE-588)1073980367 |0 (DE-627)830095640 |0 (DE-576)435490400 |4 aut | |
| 245 | 1 | 0 | |a Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion |c Maximilian Pfau, Heidi Fassnacht-Riederle, Matthias D. Becker, Nicole Graf, Stephan Michels |
| 264 | 1 | |c September 29, 2015 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.07.2020 | ||
| 520 | |a Purpose: After 48 months, unresolved macular edema secondary to central retinal vein occlusion (CRVO) is present in more than half of the patients treated with ranibizumab/bevacizumab. Switching therapy to aflibercept, a more recent vascular endothelial growth factor-A (VEGF-A) inhibitor, as well as VEGF-B and placental growth factor inhibitor, might improve the clinical outcome in patients with CRVO who respond insufficiently to ranibizumab/bevacizumab. Methods: The presented study is a retrospective analysis of CRVO patients (n = 13) responding insufficiently to ranibizumab and/or bevacizumab (requiring treatment every 6 weeks or more frequently). Treatment in these patients was switched to aflibercept, which was administered based on a ‘treat and extend' regime. The injection interval, relapse-free interval, central retinal thickness, central retinal volume, visual acuity, and intraocular pressure (IOP) were evaluated prior to switching to aflibercept and at month 6 and year 1 after switching therapy. Results: From baseline to year 1 after switching therapy to aflibercept, the mean injection interval (primary end point) increased by 0.51 months (p = 0.023) and the relapse-free interval by 3.02 weeks (p = 0.003). The mean central retinal thickness decreased by 195.84 µm and the mean central retinal volume (6 mm diameter) by -1.81 mm 3 (p = 0.007). Correspondingly, the mean ETDRS score increased from 66.15 at baseline to 76.54 letters at year 1 after switching therapy to aflibercept (+10.38 letters, p = 0.021). The IOP was not statistically significantly affected (-1.2 mm Hg, p = 0.196). Conclusion: Switching therapy from intravitreal ranibizumab/bevacizumab to aflibercept in insufficiently responding macular edema secondary to CRVO elongates the injection interval and the relapse-free interval and provides an improved anatomical as well as functional outcome. | ||
| 700 | 1 | |a Fassnacht-Riederle, Heidi |e VerfasserIn |0 (DE-588)1218097140 |0 (DE-627)1733541101 |4 aut | |
| 700 | 1 | |a Becker, Matthias D. |e VerfasserIn |0 (DE-588)135571855 |0 (DE-627)56707255X |0 (DE-576)300521871 |4 aut | |
| 700 | 1 | |a Graf, Nicole |e VerfasserIn |4 aut | |
| 700 | 1 | |a Michels, Stephan |d 1972- |e VerfasserIn |0 (DE-588)123266459 |0 (DE-627)082449724 |0 (DE-576)293629307 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ophthalmic research |d Basel : Karger, 1970 |g 54(2015), 3, Seite 150-156 |h Online-Ressource |w (DE-627)300596146 |w (DE-600)1483177-6 |w (DE-576)276271173 |x 1423-0259 |7 nnas |a Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion |
| 773 | 1 | 8 | |g volume:54 |g year:2015 |g number:3 |g pages:150-156 |g extent:7 |a Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000439223 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.karger.com/Article/FullText/439223 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200703 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 135571855 |a Becker, Matthias D. |m 135571855:Becker, Matthias D. |d 50000 |e 50000PB135571855 |k 0/50000/ |p 3 | ||
| 998 | |g 1073980367 |a Pfau, Maximilian |m 1073980367:Pfau, Maximilian |d 50000 |e 50000PP1073980367 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1703416899 |e 3695146370 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 03.07.2020"],"relHost":[{"title":[{"subtitle":"journal for research in experimental and clinical ophthalmology","title":"Ophthalmic research","title_sort":"Ophthalmic research"}],"pubHistory":["1.1970 -"],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 25.04.2019"],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"year":"2015","issue":"3","volume":"54","pages":"150-156","extent":"7","text":"54(2015), 3, Seite 150-156"},"origin":[{"publisherPlace":"Basel","dateIssuedKey":"1970","publisher":"Karger","dateIssuedDisp":"1970-"}],"id":{"issn":["1423-0259"],"zdb":["1483177-6"],"eki":["300596146"]},"disp":"Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusionOphthalmic research","recId":"300596146"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"physDesc":[{"extent":"7 S."}],"title":[{"title_sort":"Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion","title":"Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion"}],"person":[{"family":"Pfau","given":"Maximilian","role":"aut","display":"Pfau, Maximilian"},{"display":"Fassnacht-Riederle, Heidi","given":"Heidi","role":"aut","family":"Fassnacht-Riederle"},{"family":"Becker","role":"aut","given":"Matthias D.","display":"Becker, Matthias D."},{"family":"Graf","given":"Nicole","role":"aut","display":"Graf, Nicole"},{"family":"Michels","role":"aut","given":"Stephan","display":"Michels, Stephan"}],"recId":"1703416899","name":{"displayForm":["Maximilian Pfau, Heidi Fassnacht-Riederle, Matthias D. Becker, Nicole Graf, Stephan Michels"]},"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"September 29, 2015"}],"id":{"doi":["10.1159/000439223"],"eki":["1703416899"]}} | ||
| SRT | |a PFAUMAXIMICLINICALOU2920 | ||